174 Does addition of erythropoietic stimulating agents (ESAs) improve the outcome of higher-risk MDS patients treated with azacitidine (AZA)? - Itzykson, R.; Thepot, S.; Beyne-Rauzy, O.; Ame, S.; Isnard, F.; Salanoubat, C.; Taksin, A.-L.; Chelgoum, Y.; Quesnel, B.; Malfuson, J.-V.; Legros, L.; Vey, N.; et al. (Leukemia Research, 2011)